5.4716  -0.198 (-3.5%)		11-07 09:34
Open: 5.36 High: 5.4999 Volume: 9,252		Pre. Close: 5.67 Low: 5.36 Market Cap: 31(M)

Short term
Mid term
Targets	6-month :	10.98	1-year :	13.87
Resists	First :	9.4	Second :	11.88
Pivot price	7
Supports	First :	5.4	Second :	4.49
MAs	MA(5) :	5.88	MA(20) :	7.17
	MA(100) :	8.77	MA(250) :	6.43
MACD	MACD :	-0.9	Signal :	-0.7
%K %D	K(14,3) :	7.2	D(3) :	6.7
RSI	RSI(14): 36.9
52-week	High :	41.43	Low :	0.85

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HYPD ] has closed above bottom band by 13.8%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	5.93 - 5.96	5.96 - 5.99
Low:	5.4 - 5.45	5.45 - 5.48
Close:	5.6 - 5.67	5.67 - 5.73

A U.S.-based firm pivoting from ophthalmic drug-delivery tech (Optejet) to becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain; also operates a validator (“Kinetiq × Hyperion”) and continues DeFi staking strategies alongside ongoing development of Optejet UFD™ for eye care.

Wed, 02 Jul 2025
Eyenovia, Inc. will Change its Ticker to HYPD from EYEN - MarketScreener

Wed, 02 Jul 2025
Eyenovia rebrands as Hyperion DeFi, changes ticker to HYPD - Investing.com

Wed, 02 Jul 2025
Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. - Stock Titan

Wed, 02 Jul 2025
Eyenovia, Inc. Rebrands to Hyperion DeFi, Inc. and Announces Nasdaq Trading Under "HYPD" Ticker - Nasdaq

Mon, 23 Jun 2025
Eyenovia Makes Bold Crypto Move: $50M Raise Powers 1M HYPE Token Buy While FDA Device Advances - Stock Titan

Mon, 23 Jun 2025
Eyenovia Announces Closing of $50 Million Private - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	10 (M)
Held by Insiders	4.41e+006 (%)
Held by Institutions	34.3 (%)
Shares Short	1,360 (K)
Shares Short P.Month	0 (K)

EPS	-2.581e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-60 %
Return on Assets (ttm)	666.8 %
Return on Equity (ttm)	-45.2 %
Qtrly Rev. Growth	44440 %
Gross Profit (p.s.)	0
Sales Per Share	-89.01
EBITDA (p.s.)	-1.24125e+006
Qtrly Earnings Growth	-28.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.07
Price to Cash Flow	1.89

Dividend	0
Forward Dividend	1.47e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.